Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A kind of Lactobacillus reuteri and its application

A technology of Lactobacillus reuteri and bacterial agents, applied in the field of microorganisms, to achieve a wide range of application prospects, restore the effect of raising and reducing the lower area

Active Publication Date: 2020-05-12
INFINITUS (CHINA) CO LTD
View PDF11 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Therefore, so far, there is no single strain of probiotics (such as Lactobacillus reuteri) that can be colonized in the human intestine alone to relieve metabolic syndrome, or relieve hyperglycemia, hyperlipidemia, and intestinal flora imbalance. , intestinal inflammation and other symptoms and related mental diseases

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of Lactobacillus reuteri and its application
  • A kind of Lactobacillus reuteri and its application
  • A kind of Lactobacillus reuteri and its application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0107] Example 1: Lactobacillus reuteri CCFM8631 has good tolerance to simulated gastrointestinal fluid

[0108] Streak inoculation of cryopreserved Lactobacillus reuteri CCFM8631 in MRS solid medium, anaerobic static culture at 37°C for 48 hours, and subculture 2 to 3 times in MRS medium, then take Lactobacillus reuteri The culture fluid of CCFM8631 was collected by centrifugation at 8000×g for 5 min, resuspended in (1:1) artificial simulated gastric juice (MRS medium containing 1% pepsin, pH=2.5) at pH 2.5, and incubated at 37°C For anaerobic culture, samples were taken at 3 hours, and MRS agar medium was poured for culture to count plate colonies, determine the number of viable bacteria and calculate their survival rate. The survival rate is the ratio of the number of viable bacteria when sampling in the culture solution to the number of viable bacteria at the 0th hour, expressed in %.

[0109] Take the culture solution of Lactobacillus reuteri CCFM8631, centrifuge at 8000...

Embodiment 2

[0113] Example 2: Lactobacillus reuteri CCFM8631 has no toxic side effects on SD rats

[0114] Suspend Lactobacillus reuteri CCFM8631 in 2% sucrose solution to make a concentration of 3.0×10 9 CFU / mL bacterial suspension. Take 8 healthy male SD rats with a body weight of about 180g-200g. After adapting to the environment for a week, they are given the above-mentioned concentration of bacterial suspension by gavage once a day. . The results are shown in Table 3.

[0115] Table 3 Changes in body weight and death of rats

[0116] time (days) 1 2 3 4 5 6 7 weight(g) 228.2±0.9 235.3±1.1 241.1±0.5 246.7±0.7 252.0±0.2 258.2±1.3 264.5±0.4 Circumstances of death - - - - - - -

[0117] Note: -: Rats did not die

[0118] The results showed that the feeding concentration was 3.0×10 9 The suspension of Lactobacillus reuteri CCFM8631 in CFU / mL had no significant effect on rats, no significant change in body weight, and no death. The appear...

Embodiment 3

[0119] Example 3: Lactobacillus reuteri CCFM8631 has a good recovery effect on tissue damage such as liver and duodenum in rats with metabolic syndrome

[0120] Forty-eight healthy male SD rats with a body weight of 180-200 g were taken, adapted to the environment for 1 week, and randomly divided into 6 groups: blank control group (NC), high-sugar and high-fat model control group (HFHS), simvastatin control group (SC ), rosiglitazone control group (RH), Lactobacillus reuteri CCFM8631 intervention group (CCFM8631), Lactobacillus rhamnosus GG control group (LGG), each group contained 8 mice, and intragastric administration of bacteria suspension The concentration is 3.0×10 9 CFU / mL, resuspended in 2% sucrose solution. The grouping and treatment methods of the experimental animals are shown in Table 4.

[0121] Table 4 Grouping and treatment of experimental animals

[0122]

[0123]

[0124] At the end of the experiment, the rats were fasted for 12 hours, anesthetized by...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
thicknessaaaaaaaaaa
Login to View More

Abstract

The invention relates to the technical field of microorganisms, and discloses a lactobacillus reuteri and its application. The preservation number of Lactobacillus reuteri CCFM8631 of the present invention is CGMCC No.14394, which can significantly improve the level of rat peripheral blood neurotransmitter 5-serotonin; restore the rat peripheral blood testosterone hormone level caused by a high-sugar and high-fat diet and the abnormal abundance of Blautia, Turicibacter, Oscillospira and Bifidobacterium in the intestinal flora; tolerance to simulated gastrointestinal fluid, rapid colonization in the intestinal tract, significantly improved the liver of rats with metabolic syndrome caused by high-sugar and high-fat diet , pathological damage of the duodenum and elevated levels of triglyceride and total cholesterol in serum, used to prevent, slow down or treat metabolic disorders such as metabolic syndrome, irritable bowel syndrome and anxiety and depression related to metabolic syndrome and other mental illness.

Description

technical field [0001] The present invention relates to the technical field of microorganisms, in particular to a Lactobacillus reuteri and its use, especially a Lactobacillus reuteri capable of regulating intestinal flora, regulating the brain-gut axis, and significantly alleviating metabolic syndrome and its use . Background technique [0002] In recent years, with the development of the economy, the lifestyle of the people in our country has changed significantly, the amount of activity has decreased, the proportion of obesity has increased significantly, and the prevalence of diabetes and metabolic syndrome (Metabolic Syndrome) has increased significantly. Epidemiological surveys show that about 20%-30% of adults worldwide suffer from metabolic syndrome. In 2013, the results of a multi-center, multi-level stratified large-scale sampling survey organized by the Diabetes Society of the Chinese Medical Association showed that the prevalence of metabolic syndrome among peop...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C12N1/20A23C9/123A23C13/16A23C19/032A23C19/06A23C11/10A23L11/00A23L19/00A23L33/135A61K35/747A61P25/22A61P25/24A61P3/06A61P3/10A61P1/16A61P1/00C12R1/225A23L11/50
CPCA23L19/00A23L33/135A23C9/1234A23C11/106A23C13/16A23C19/0323A23C19/062C12N1/20A23V2002/00A61K2035/115A23L11/50C12R2001/225C12N1/205A23L11/65A23V2400/173A23V2200/3204A23V2200/30A23V2200/3262A23V2200/328A61P3/00A61P1/00A61K35/747
Inventor 马方励陈卫王刚朱广素王园园肖凌云胡明华张灏赵建新马忠华
Owner INFINITUS (CHINA) CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products